Research advances in the clinical effect of tenofovir alafenamide in treatment of chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1828-1833, 2019.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-779053
Responsible library:
WPRO
ABSTRACT
Tenofovir alafenamide (TAF) is a novel nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis B virus (HBV) infection. Compared with tenofovir disoproxil fumarate, TAF has better plasma stability and stronger liver-targeting ability and can significantly reduce the adverse events of renal injury and reduced bone mineral density. This article summarizes the research advances in the pharmacological characteristics, metabolic pathways, drug interactions, drug resistance, and renal safety of TAF and its role in patients with chronic HBV infection.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2019
Document type:
Article